Get to know our clinical trials

Clinical trial of PHE885, B-cell maturation antigen-targeted CAR-T lymphocytes, in adult participants with relapsed and refractory multiple myeloma.

THE PURPOSE OF THE STUDY IS TO TEST AN EXPERIMENTAL METHOD CALLED MODIFIED T-LYMPHOCYTE THERAPY FOR MULTIPLE MYELOMA. T LYMPHOCYTES (A TYPE OF LEUKOCYTE) TAKEN FROM YOUR BLOOD WILL BE GENETICALLY MODIFIED TO PRODUCE A RECEPTOR CALLED "CHIMERIC ANTIGEN RECEPTOR" (CAR) ON THE SURFACE OF THESE T LYMPHOCYTES, WHICH ALLOWS THEM TO RECOGNIZE CELLS THAT EXPRESS A PROTEIN CALLED BCMA (B CELL MATURATION ANTIGEN), LOCATED ON THE SURFACE OF MULTIPLE MYELOMA TUMOR CELLS, AND ALSO ON NORMAL PLASMA CELLS AND GERMINAL CENTER B CELLS.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • A PHASE 2 STUDY OF PHE885, B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CAR-T CELLS IN ADULT PARTICIPANTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
  • Code EudraCT: 2021-003747-22
  • Protocol number: CPHE885B12201
  • Promoter: Novartis Farmaceutica
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.